

LIBBY STUDY OVERVIEW

<https://libbystudy.org/>

The **LiBBY Study** (Life's-end Benefits of cannaBidiol and tetraHYdrocannabinol) is a national clinical trial showing that an oral THC and CBD oil combination significantly reduces severe agitation in late-stage Alzheimer's and dementia patients.

Study Design and Results

- **Participants:** 120 hospice-eligible individuals (average age 80) with advanced dementia and significant agitation.
- **Treatment:** A 12-week randomized, double-blind, placebo-controlled trial testing an oral liquid combination of THC and CBD.
- **Key Finding:** Within two weeks, patients taking the cannabis-derived oil saw a 6.27-point greater reduction in agitation scores (measured by the Cohen-Mansfield Agitation Inventory) compared to placebo.
- **Safety:** Nearly 90% of active-arm patients had sustained behavioral improvement with a safety profile similar to the placebo, offering a safer alternative to heavy sedatives.
- **Backing:** Funded by the National Institute on Aging (NIA) and coordinated through the Alzheimer's Clinical Trials Consortium.

The Association can provide more details on:

- **The specific dosage** used in the trial
- **How to contact** or look into the LiBBY Study
- **Other current treatments** for dementia-related agitation

Cannabis-Based Treatment Shows Promise for Calming Agitation in Late-Stage Dementia

A combination of two compounds found in cannabis, THC and CBD, significantly reduced agitation in people with advanced Alzheimer's and other dementias in the LiBBY Phase 2 clinical trial.

Agitation affects about half of people living with dementia near the end of life and is one of the most distressing symptoms for patients, families, and caregivers. In the study of 120 participants with severe dementia, benefits were seen within just two weeks of starting treatment. Nearly 90% of patients receiving the treatment showed overall improvement after 12 weeks, compared to 25% on placebo.

This experimental treatment was created specifically for this research study and is not available to the public. Caregivers should never give cannabis or cannabis-related products to a loved one living with any disease that causes dementia without first consulting a doctor.

LiBBY, which was conducted by the National Institute on Aging-funded Alzheimer's Clinical Trial Consortium, is among the first randomized, controlled trials in a hospice-

LIBBY STUDY OVERVIEW

eligible population with dementia. The Alzheimer's Association supports all legitimate avenues of dementia research, and encourages patients, caregivers, and clinicians to engage in shared decision-making when considering treatment options. Visit [alz.org](https://www.alz.org) to learn more.